Oxford Immunotec
8
0
0
6
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 75/100
25.0%
2 terminated/withdrawn out of 8 trials
75.0%
-11.5% vs industry average
0%
0 trials in Phase 3/4
0%
0 of 6 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (8)
Clinical Concordance Evaluation of T-SPOT®.TB Assay Performance (T-Cell SelectTM Study)
Role: lead
Assessing the Ability of the T-SPOT®.TB Test (IQ)
Role: lead
Assessing the Ability of the T-SPOT®.TB Test
Role: lead
Evaluating the Clinical Utility of the T-SPOT.CMV Assay for the Prediction of CMV Reactivation Among Pediatric Patients Undergoing Hematopoietic Cell Transplant
Role: collaborator
T-SPOT.CMV and T-SPOT.PRT Diagnostic Assays
Role: lead
Lyme Test Indication Combinations (LyTIC) Study
Role: lead
Observational Trial to Evaluate Hematopoietic Stem Cell Transplantation CMV Reactivation
Role: lead
Tuberculosis (TB) Screening for the Diagnosis of Latent TB in Immunocompromised Populations
Role: collaborator
All 8 trials loaded